FilingSEC EDGAR6-K
Enlivex Therapeutics Proposes Reverse Share Split to Maintain Nasdaq Listing
· SEC accepted
StageShareholder meeting scheduled
Filing content
Enlivex Therapeutics will hold an extraordinary general meeting on October 14, 2026, to vote on a 1-for-16 reverse share split to satisfy Nasdaq's minimum bid price requirement.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…